Compare APAM & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APAM | CELC |
|---|---|---|
| Founded | 1994 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.1B |
| IPO Year | 2013 | 2017 |
| Metric | APAM | CELC |
|---|---|---|
| Price | $41.08 | $99.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $47.00 | ★ $100.13 |
| AVG Volume (30 Days) | 507.5K | ★ 883.6K |
| Earning Date | 02-03-2026 | 11-12-2025 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | ★ 2.95 | N/A |
| EPS | ★ 3.71 | N/A |
| Revenue | ★ $1,158,234,000.00 | N/A |
| Revenue This Year | $8.38 | N/A |
| Revenue Next Year | $6.56 | N/A |
| P/E Ratio | $11.25 | ★ N/A |
| Revenue Growth | ★ 8.88 | N/A |
| 52 Week Low | $32.75 | $7.58 |
| 52 Week High | $48.50 | $112.64 |
| Indicator | APAM | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 40.79 | 54.37 |
| Support Level | $41.50 | $98.76 |
| Resistance Level | $42.04 | $103.09 |
| Average True Range (ATR) | 0.69 | 4.13 |
| MACD | 0.05 | -1.19 |
| Stochastic Oscillator | 47.79 | 16.85 |
Artisan Partners Asset Management Inc is a investment management firm providing a range of investment strategies to a diverse group of clients around the world. Each of the company's strategies is managed by one of its several investment teams. Investment management services are offered to institutions through separate accounts and mutual funds. Artisan's investment offerings include several long-only, equity investment strategies across a multitude of market capitalization segments and investing styles in both the United States and international markets. In addition to its equity strategies, customers may invest in a fixed-income strategy. Strategies are often distributed to customers ranging from retail investors to institutional investors through specialized channels.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.